Contact:Goga Radakovic
Phone:(434)243-5750
E-mail:gr2p@virginia.edu
UVa Health System seeks adults with Glioblastoma for research study
Glioblastoma multiforme (GBM) is a malignant brain tumor. The usual treatments are: surgery, radiation therapy and chemotherapy. Unfortunately, these tumors are resistant to most treatments and typically recur within months of treatment. These tumors are the second leading cause of death from cancers in people under the age of 35 and the fourth leading cause in those under the age of 54. There is no cure for this kind of tumor, and many people with this tumor die in 12-15 months.
In this study, researchers will be looking at the survival rate of those treated with an investigational medicine called Zactima (Vandetanib) in combination with standard radiation treatment and the standard chemotherapeutic agent Temozolomide. Participants will have a routine history and physical exam performed, tumor evaluations by magnetic resonance imaging (MRI), and routine blood tests.
You may qualify for the study is you:
" Are a male or non-pregnant female age 18 or older
" Have had surgical biopsy or surgical removal of the tumor. (Note: you must start study treatment greater than 1 week after, but less than 4 weeks after biopsy or surgery)
" Are willing to practice effective method of birth control during study participation
You may not qualify for this study if you have/had:
" Other active cancers requiring therapy to control disease
" Prior chemotherapy or radiation therapy for any brain tumor
" Had any prior anti-tumor treatment (other than corticosteroids) including any investigational agents
OR you are
" Receiving any other investigational agents
" Pregnant women or nursing women
You will receive no money for being part of this study. Study drug will be provided by AstraZeneca.
For more information or to see if you qualify, please contact:
Contact: Goga Radakovic
Phone: (434) 243-5750
Email: gr2p@virginia.edu
Primary Investigator: David Schiff, MD Accepts adult enrollment: YES
IRB-HSR# 13291
|
|
Primary Investigator: Schiff David,